Spex Capital, an early-stage investor in healthtech solutions to help overcome the world’s healthcare challenges, announces the launch of the Spex Venture HealthTech Fund. With a target size of €100m, the closed-end fund will invest globally in early-stage healthtech ventures, from seed to Series A, up to €5M. The fund is a designated Article 9 impact fund under the EU’s Sustainable Finance Disclosure Regulation (SFDR).
Founded by serial healthtech entrepreneur, Claudio D’Angelo, Spex Capital has closed 10 investments in this space, as it looks to broaden its investment into founders with the vision to back the innovators in healthcare.
Through an exclusive two-year partnership with MedCity, the life sciences cluster organisation for London, Spex Capital benefits from connections to the NHS in England and extensive reach across the wider ecosystem. Joint activities include an international investment programme that contributes to the flow of around 1,000 healthcare companies developing breakthrough technologies every year.
Claudio D’Angelo, Founder and CEO of Spex Capital, said:
“Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre Senior Advisors, we will have unparalleled access to invest in the best startups within this space.”
Spex Capital’s global reach will also be bolstered by the appointment of Brent Stackhouse, the Managing Director of Mount Sinai Ventures, to the team. Stackhouse has a wealth of experience from his time investing in the US healthcare system and will offer a strong springboard for the overseas expansion of the companies the fund will invest in.
Brent Stackhouse, Senior Partner, Mount Sinai Ventures, said:
“I’m excited to take part in the launch of the Spex Venture HealthTech Fund at a time of radical change for the healthtech sector. History has shown us time and time again that economic downturns provide an impetus for innovation and that some of the strongest vintages have come from recession years. We now have an opportunity to acquire high quality assets at discounted valuations. We look forward to shaping the global healthcare ecosystem by helping innovators in developing ground-breaking technologies and solutions to overcome healthcare challenges worldwide.”
About Spex Capital
Spex Capital is a digital health and med-tech investment management firm specialised in investing in and advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally.
Founded in 2021 by serial health-tech entrepreneur Claudio D’Angelo, Spex Capital has an ongoing partnership with MedCity – which represents London’s life sciences cluster, collaborating with the city’s leading academic centres to connect private industry with partners in the NHS, the charity sector and research institutes.
With an already strong portfolio of six high-growth companies and an impressive team’s track record of past investments, the firm reviews on average 1,000 early stage ventures a year, looking for the most promising candidates and offering tickets up to €5,000,000.
About Spex Venture HealthTech Sub-Fund
Spex Venture Health-Tech Sub-Fund (hereafter, the Sub-Fund) is an investment compartment of Spex Venture Fund, S.C.A. SICAV-RAIF (hereafter, the Fund). The Fund is a corporate partnership limited by shares (société en commandite par actions) incorporated under the laws of the Grand Duchy of Luxembourg as an investment company with variable capital qualifying as a reserved alternative investment fund (société d’investissement à capital variable – fonds d’investissement alternatif réservé) under the Luxembourg law of 23 July 2016 relating to reserved alternative investments funds, as amended or supplemented from time to time.
The Fund is supported and serviced by top tier institutions and market specialists like Crédit Suisse (independent administrator, registrar, transfer agent and depositary bank), One Fund Management S.A. (third party alternative investment fund manager), Stibbe Avocats (legal counsel) and Deloitte Audit (statutory auditor).
For the purpose of investors in the EU, this announcement qualifies as a marketing communication in accordance with the Regulation (EU) 2019/1156 of the European Parliament and of the Council of 20 June 2019 on facilitating cross-border distribution of collective investment undertakings and the ESMA Guidelines on marketing communications under the Regulation on cross-border distribution of funds.
This press release does not constitute or form part of, and should not be construed as, an offer, invitation or inducement or recommendation to make an investment in the Sub-Fund nor shall it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.
The Sub-Fund is suitable only for “professional investors” (within the meaning of the EU Directive 2014/65/EU on markets in financial instruments) domiciled or with a registered office in jurisdictions where the Sub-Fund is authorised for marketing.
The full details of the investment features, risks and costs related to the Sub-Fund are disclosed in the placement memorandum of the Fund.
